fda warning bpc-157 not approved panel backs compounded BPC-157, KPV peptides in win for RFK Jr FDA scientists flag concerns with

Molecular identity requires suitable supporting analysis

Specifically, the panel will assess whether those substances should be moved off the Category 2 list a designation reserved for bulk drug substances that present potential safety risks and are therefore ineligible for routine compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act

Microdosing GLP-1 or GLP-1/GIP refers to using lower doses of the medication to support long-term health and longevity, rather than for diabetes or weight management

Avoid experiencing these harsh truths first-hand by testing often

We prioritise your wellbeing every day